Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 11/30104% above fair value
$168.08+0.13 (+0.08%)
Close on Nov 13, 2026Market cap $208.48BP/E –Yield 1.88%
Gilead Sciences total assets
Total assets on the balance sheet at the end of each period.
Gilead Sciences's total assets was $51.41B at Sep 30, 2026. For fiscal 2025 it was $59.02B, up 0.0% from the year before. Over ten years it grew 1.3% a year on average. The highest annual figure on record is $70.28B in fiscal 2017.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $59.02B | +0.0% |
| FY2024 | Dec 31, 2024 | $59.00B | -5.0% |
| FY2023 | Dec 31, 2023 | $62.13B | -1.7% |
| FY2022 | Dec 31, 2022 | $63.17B | -7.0% |
| FY2021 | Dec 31, 2021 | $67.95B | -0.7% |
| FY2020 | Dec 31, 2020 | $68.41B | +11.0% |
| FY2019 | Dec 31, 2019 | $61.63B | -3.2% |
| FY2018 | Dec 31, 2018 | $63.68B | -9.4% |
| FY2017 | Dec 31, 2017 | $70.28B | +23.4% |
| FY2016 | Dec 31, 2016 | $56.98B | +10.2% |
| FY2015 | Dec 31, 2015 | $51.72B | +49.2% |
| FY2014 | Dec 31, 2014 | $34.66B | +53.5% |
| FY2013 | Dec 31, 2013 | $22.58B | +6.3% |
| FY2012 | Dec 31, 2012 | $21.24B | +22.8% |
| FY2011 | Dec 31, 2011 | $17.30B | +49.3% |
| FY2010 | Dec 31, 2010 | $11.59B | +19.5% |
| FY2009 | Dec 31, 2009 | $9.70B | +39.8% |
| FY2008 | Dec 31, 2008 | $6.94B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $51.41B | -12.2% |
| Q2 FY2026 | Jun 30, 2026 | $49.36B | -11.4% |
| Q1 FY2026 | Mar 31, 2026 | $56.28B | -0.3% |
| Q4 FY2025 | Dec 31, 2025 | $59.02B | +0.0% |
| Q3 FY2025 | Sep 30, 2025 | $58.53B | +7.4% |
| Q2 FY2025 | Jun 30, 2025 | $55.72B | +4.0% |
| Q1 FY2025 | Mar 31, 2025 | $56.43B | +0.3% |
| Q4 FY2024 | Dec 31, 2024 | $59.00B | -5.0% |
| Q3 FY2024 | Sep 30, 2024 | $54.53B | -12.6% |
| Q2 FY2024 | Jun 30, 2024 | $53.58B | -14.0% |
| Q1 FY2024 | Mar 31, 2024 | $56.29B | -9.0% |
| Q4 FY2023 | Dec 31, 2023 | $62.13B | -1.7% |
| Q3 FY2023 | Sep 30, 2023 | $62.37B | -0.3% |
| Q2 FY2023 | Jun 30, 2023 | $62.34B | -0.8% |
| Q1 FY2023 | Mar 31, 2023 | $61.88B | -1.9% |
| Q4 FY2022 | Dec 31, 2022 | $63.17B | -7.0% |
| Q3 FY2022 | Sep 30, 2022 | $62.56B | -6.8% |
| Q2 FY2022 | Jun 30, 2022 | $62.87B | -7.5% |
| Q1 FY2022 | Mar 31, 2022 | $63.08B | -6.5% |
| Q4 FY2021 | Dec 31, 2021 | $67.95B | -0.7% |
| Q3 FY2021 | Sep 30, 2021 | $67.10B | +10.2% |
| Q2 FY2021 | Jun 30, 2021 | $67.98B | +21.5% |
| Q1 FY2021 | Mar 31, 2021 | $67.49B | +13.0% |
| Q4 FY2020 | Dec 31, 2020 | $68.41B | +11.0% |
| Q3 FY2020 | Sep 30, 2020 | $60.88B | +2.9% |
| Q2 FY2020 | Jun 30, 2020 | $55.93B | -11.5% |
| Q1 FY2020 | Mar 31, 2020 | $59.74B | -4.9% |
| Q4 FY2019 | Dec 31, 2019 | $61.63B | -3.2% |
| Q3 FY2019 | Sep 30, 2019 | $59.15B | -8.0% |
| Q2 FY2019 | Jun 30, 2019 | $63.21B | -3.3% |
| Q1 FY2019 | Mar 31, 2019 | $62.84B | -3.9% |
| Q4 FY2018 | Dec 31, 2018 | $63.68B | -9.4% |
| Q3 FY2018 | Sep 30, 2018 | $64.31B | -0.6% |
| Q2 FY2018 | Jun 30, 2018 | $65.36B | +8.4% |
| Q1 FY2018 | Mar 31, 2018 | $65.38B | +13.3% |
| Q4 FY2017 | Dec 31, 2017 | $70.28B | +23.4% |
| Q3 FY2017 | Sep 30, 2017 | $64.66B | – |
| Q2 FY2017 | Jun 30, 2017 | $60.26B | – |
| Q1 FY2017 | Mar 31, 2017 | $57.70B | – |
| Q4 FY2016 | Dec 31, 2016 | $56.98B | – |
See a number that looks wrong?